NASDAQ:CDXC ChromaDex (CDXC) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CDXC Stock Alerts $3.50 -0.17 (-4.63%) (As of 02:53 PM ET) Add Compare Share Share Today's Range$3.17▼$3.7750-Day Range$1.36▼$3.8452-Week Range$1.25▼$4.06Volume409,006 shsAverage Volume221,772 shsMarket Capitalization$263.59 millionP/E RatioN/ADividend YieldN/APrice Target$5.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ChromaDex alerts: Email Address ChromaDex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside65.7% Upside$5.80 Price TargetShort InterestHealthy2.62% of Float Sold ShortDividend StrengthN/ASustainability-1.83Upright™ Environmental ScoreNews Sentiment1.11Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.02) to $0.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.32 out of 5 starsMedical Sector145th out of 938 stocksMedicinals & Botanicals Industry1st out of 11 stocks 3.5 Analyst's Opinion Consensus RatingChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.80, ChromaDex has a forecasted upside of 65.7% from its current price of $3.50.Amount of Analyst CoverageChromaDex has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.62% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in ChromaDex has recently decreased by 3.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldChromaDex does not currently pay a dividend.Dividend GrowthChromaDex does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChromaDex has received a 56.21% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Dietary supplements" products. See details.Environmental SustainabilityThe Environmental Impact score for ChromaDex is -1.83. Previous Next 4.0 News and Social Media Coverage News SentimentChromaDex has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ChromaDex this week, compared to 1 article on an average week.Search Interest10 people have searched for CDXC on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows9 people have added ChromaDex to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChromaDex insiders have not sold or bought any company stock.Percentage Held by Insiders10.57% of the stock of ChromaDex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.41% of the stock of ChromaDex is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ChromaDex are expected to grow in the coming year, from ($0.02) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChromaDex is -49.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChromaDex is -49.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChromaDex has a P/B Ratio of 9.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About ChromaDex Stock (NASDAQ:CDXC)ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Read More CDXC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXC Stock News HeadlinesMarch 27, 2024 | stocknews.com3 Chemical Stocks Poised for GainsMarch 27, 2024 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Shares Cross Above 200-Day Moving Average of $1.57March 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 26, 2024 | businesswire.comChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramMarch 8, 2024 | finance.yahoo.comChromaDex Full Year 2023 Earnings: EPS Beats ExpectationsMarch 8, 2024 | uk.sports.yahoo.comPersona 3 Reload is getting the DLC it needs, but not the one it deservesMarch 7, 2024 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDAMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 6, 2024 | markets.businessinsider.comWhat Wall Street expects from ChromaDex's earningsMarch 6, 2024 | investorplace.comCDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023March 6, 2024 | benzinga.comEarnings Preview For ChromaDexMarch 6, 2024 | finance.yahoo.comChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 ResultsMarch 2, 2024 | finance.yahoo.comInsiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the companyFebruary 21, 2024 | finance.yahoo.comChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024February 21, 2024 | businesswire.comChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024February 6, 2024 | entrepreneur.comTop 3 Accelerating Chemical Stocks to ConsiderFebruary 5, 2024 | finance.yahoo.comChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024January 26, 2024 | finance.yahoo.comChromaDex to Present at the Lytham Partners 2024 Investor Select ConferenceJanuary 24, 2024 | seekingalpha.comChromaDex: Growth At A Reasonable PriceJanuary 19, 2024 | finance.yahoo.comChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To ProfitDecember 20, 2023 | businesswire.comChromaDex Supports the US Military with its Industry Leading NAD + Supplement, Tru NiagenDecember 20, 2023 | baystreet.caChromaDex Flat on Assistance to MilitaryDecember 20, 2023 | finance.yahoo.comChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®November 30, 2023 | finance.yahoo.comA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)November 28, 2023 | finance.yahoo.comAn Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% UndervaluedNovember 15, 2023 | businesswire.comNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor ...See More Headlines Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2023Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:CDXC CUSIPN/A CIK1386570 Webwww.chromadex.com Phone(310) 388-6706Fax949-419-0294Employees106Year FoundedN/APrice Target and Rating Average Stock Price Target$5.80 High Stock Price Target$6.60 Low Stock Price Target$5.00 Potential Upside/Downside+73.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,940,000.00 Net Margins-5.91% Pretax Margin-5.91% Return on Equity-17.81% Return on Assets-9.17% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio1.70 Sales & Book Value Annual Sales$83.57 million Price / Sales3.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book8.79Miscellaneous Outstanding Shares75,310,000Free Float67,349,000Market Cap$251.54 million OptionableOptionable Beta1.87 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Frank Louis Jaksch Jr. (Age 56)Co-Founder & Chairman Comp: $292.27kMr. Robert N. Fried (Age 64)CEO & Director Comp: $735.54kMs. Brianna Gerber (Age 43)Chief Financial Officer Comp: $509.82kDr. Andrew Shao Ph.D.Senior Vice President of Global Regulatory & Scientific AffairsHeather Van BlarcomSenior VP of Legal & Corporate SecretaryAlex WorshamVice President of Global Marketing & CommunicationsMr. David KroesSenior Vice President of People MattersMs. Chu YanManaging Director of Asia PacificMr. Jason CampbellSenior Vice President of Business DevelopmentKendall KnyschHead of Media Relations & PartnershipsMore ExecutivesKey CompetitorsAurora CannabisNASDAQ:ACBMenlo TherapeuticsNASDAQ:FOMXMind Medicine (MindMed)NASDAQ:MNMDMediWoundNASDAQ:MDWDbioteNASDAQ:BTMDView All CompetitorsInsiders & InstitutionsRoyal Bank of CanadaBought 34,448 shares on 2/14/2024Ownership: 0.158%Gabelli Funds LLCBought 20,000 shares on 2/13/2024Ownership: 0.266%Tieton Capital Management LLCBought 461,692 shares on 2/9/2024Ownership: 3.879%International Assets Investment Management LLCBought 8,600 shares on 1/24/2024Ownership: 0.038%Silverberg Bernstein Capital Management LLCBought 82,757 shares on 1/17/2024Ownership: 0.110%View All Insider TransactionsView All Institutional Transactions CDXC Stock Analysis - Frequently Asked Questions Should I buy or sell ChromaDex stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDXC shares. View CDXC analyst ratings or view top-rated stocks. What is ChromaDex's stock price target for 2024? 1 Wall Street analysts have issued 12 month target prices for ChromaDex's stock. Their CDXC share price targets range from $5.00 to $6.60. On average, they predict the company's stock price to reach $5.80 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price. View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts. How have CDXC shares performed in 2024? ChromaDex's stock was trading at $1.43 at the beginning of 2024. Since then, CDXC shares have increased by 134.3% and is now trading at $3.35. View the best growth stocks for 2024 here. When is ChromaDex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CDXC earnings forecast. How were ChromaDex's earnings last quarter? ChromaDex Co. (NASDAQ:CDXC) announced its earnings results on Wednesday, March, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business earned $21 million during the quarter, compared to the consensus estimate of $21.08 million. ChromaDex had a negative trailing twelve-month return on equity of 17.81% and a negative net margin of 5.91%. During the same quarter in the prior year, the company earned ($0.08) earnings per share. What is Robert Fried's approval rating as ChromaDex's CEO? 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend. What other stocks do shareholders of ChromaDex own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL). Who are ChromaDex's major shareholders? ChromaDex's stock is owned by many different retail and institutional investors. Top institutional shareholders include Tieton Capital Management LLC (3.88%), Gabelli Funds LLC (0.27%), Royal Bank of Canada (0.16%), Silverberg Bernstein Capital Management LLC (0.11%), International Assets Investment Management LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brianna Gerber, Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Robert N Fried and Steven D Rubin. View institutional ownership trends. How do I buy shares of ChromaDex? Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDXC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.